Back to Portfolio
AVEX

AEVEX Corp

$39.01 4.4B market cap April 20, 2026
AEVEX Corp AVEX BUFFETT / MUNGER / KLARMAN SUMMARY
1 SNAPSHOT
Price$39.01
Market Cap4.4B
2 BUSINESS

AEVEX is a legitimate defense technology company riding the most significant shift in warfare since the adoption of precision-guided munitions. Its combat- proven Phoenix Ghost loitering munitions, proprietary CompassX GPS-denied autonomy platform, and 99% recompete win rate demonstrate real competitive advantages. However, at $39/share (nearly 2x IPO price, 10x 2025 revenue), the stock is priced for a future that assumes flawless execution of an $8.1B pipeline, sustained margin expansion from a 21.8% gross margin base, and continued defense budget growth -- all by a newly public company with negative free cash flow, a controlling PE shareholder preparing to exit, and a $367.5M Tax Receivable Agreement that structurally disadvantages public shareholders. The business deserves a place on the watchlist; the current valuation demands patience. Wait for the lockup expiration, 2-3 quarters of public earnings history, and a price closer to $12-18 before considering a position.

3 MOAT NARROW

Security clearances, classified program relationships, combat-proven track record (5,000+ Phoenix Ghost deliveries), CompassX GPS-denied autonomy platform (9 patents), 99% recompete win rate, ForgeX forward-deployable manufacturing

4 MANAGEMENT
CEO: Roger Wells

Average - IPO proceeds used to repay $257.8M PE debt rather than invest in growth; TRA structure prioritizes PE returns over public shareholders

5 ECONOMICS
-3.9% Op Margin
-2.5% ROIC
-3.9% ROE
-260x P/E
-0.105B FCF
Net Cash Debt/EBITDA
6 VALUATION
FCF Yield-2.4%
DCF Range10 - 18

Overvalued by 117-290%; IPO euphoria + defense sector momentum

7 MUNGER INVERSION
Kill Event Severity P() E[Loss]
Extreme revenue concentration in EUCOM Deep Strike contract ($645.7M); Q1 283% growth is single-program driven HIGH - -
Madison Dearborn Partners 79.1% voting control with lockup expiration ~October 2026 creating massive share supply overhang MED - -
8 KLARMAN LENS
Downside Case

Extreme revenue concentration in EUCOM Deep Strike contract ($645.7M); Q1 283% growth is single-program driven

Why Market Right

Lockup expiration ~October 2026 (MDP 79.1% stake eligible for sale); EUCOM contract completion/slowdown could collapse revenue growth; Gross margin compression: 28.1% (2024) to 21.8% (2025); Competition intensifying from Anduril ($28B+), Shield AI, AVAV; TRA payments of ~$367.5M over 15 years draining cash from public shareholders

Catalysts

Global rearmament trend: NATO 5% GDP target, U.S. defense budget +13% YoY; Pipeline conversion: $8.1B pipeline with 28.4% win rate = $2.3B potential; International FMS expansion: 55 allied-nation engagements in development; Army LE-SR program win establishing new customer relationships; Annualized Q1 2026 revenue run-rate of $800M+ implies near-doubling

9 VERDICT WAIT
C+ Quality Weak - Newly public, FCF-negative, $367.5M TRA obligation acts as structural cash drain; post-IPO balance sheet clean but limited cash reserves
Strong Buy$12
Buy$18
Fair Value$18

Add to watchlist. Do NOT buy at current prices. Monitor for post-lockup entry opportunity ~October 2026 or if shares trade back toward $12-18 range.

🧠 ULTRATHINK Deep Philosophical Analysis

AEVEX Corp (AVEX) - Deep Philosophical Analysis

The Core Question: Is This the Next Great Defense Franchise, or a PE Exit Dressed in Camo?

There is a saying in venture capital that the best time to invest in a paradigm shift is before the paradigm shifts. By the time everyone agrees that drones have changed warfare, the easy money has already been made. The hard question for AEVEX is whether the public market is arriving early enough to the party -- or whether Madison Dearborn Partners is handing us the check on their way out the door.

Let us be precise about what AEVEX actually is. Strip away the defense-tech buzzwords -- "autonomous systems," "sensor fusion," "GPS-denied operations" -- and you find a company that does two things. First, it builds expendable drones that fly into targets and explode (Phoenix Ghost loitering munitions). Second, it operates manned aircraft equipped with surveillance equipment for intelligence agencies (the legacy ISR business). The first business is growing explosively. The second provides stable but unexciting cash flows. The IPO is priced as if both businesses are the first one.

The Phoenix Ghost program is genuinely impressive. Developed in response to an urgent DoD request as Russia invaded Ukraine, AEVEX delivered thousands of loitering munitions to an active combat zone within months. The company demonstrated something that most defense contractors cannot: the ability to move at startup speed with military-grade reliability. Nine-day order-to-delivery windows. Monthly production of 330 units at peak. Over 5,000 systems fielded. This is not vaporware.

But -- and this is the inversion that Munger would insist upon -- what exactly is the moat around an expendable drone?

Moat Meditation: The Paradox of the Disposable Weapon

A loitering munition, by its nature, is designed to be destroyed on first use. It is the opposite of a F-35, which generates decades of maintenance revenue. Each Phoenix Ghost flies once and ceases to exist. This means AEVEX must continuously win new orders to maintain revenue -- there is no installed base generating recurring income. The business model is closer to ammunition manufacturing than to aircraft production.

This matters enormously for moat assessment. The defense primes -- Lockheed, Raytheon, Northrop -- derive their widest moats from platforms that create decades of maintenance, upgrade, and ammunition lock-in. A fleet of F-35s is an annuity. A fleet of Phoenix Ghosts is a purchase order that expires when the last drone detonates.

AEVEX's moat, such as it is, rests on three pillars: the CompassX autonomy software, the classified customer relationships, and the combat track record. CompassX is genuinely differentiated -- GPS-denied navigation using visual odometry is a hard technical problem, and the nine patents provide some protection. But patents in defense technology are a weak moat. The real barrier is the classified nature of the algorithms and the combat data that trains them. You cannot replicate what you cannot see, and competitors cannot access AEVEX's classified performance data.

The customer relationships are stickier than they appear. The 99% recompete win rate is the most important number in the entire S-1 filing. In classified programs, switching contractors means re-vetting an entirely new workforce, re-establishing secure facilities, and accepting months of integration risk during active operations. No program manager will accept that risk to save 5% on a contract. This is the moat -- not the technology itself, but the institutional inertia of the national security apparatus.

Yet I must be honest about the limits. Anduril Industries, valued at $28 billion in private markets, is building precisely the same capabilities with vastly more capital and arguably better software talent. Shield AI is pursuing autonomous flight with deep pockets. AeroVironment, already public at $14 billion market cap, has its own loitering munition platform (Switchblade) with significant combat deployment. AEVEX is fighting above its weight class in a market that is attracting the best-funded competitors in defense history.

The Owner's Mindset: Would Buffett Own This for 20 Years?

Warren Buffett would not touch AEVEX with a ten-foot pole, and for good reasons.

First, the business has no demonstrated earning power. It lost money in 2024 (-$78.6M) and 2025 (-$16.8M). The Q1 2026 profitability is encouraging but represents a single quarter driven by a single contract. Buffett requires years -- preferably decades -- of consistent earning power before investing.

Second, the governance structure is antithetical to everything Buffett values. Madison Dearborn Partners controls 79.1% of voting power. The Tax Receivable Agreement directs 85% of certain tax savings to pre-IPO holders. The company is a "controlled company" exempt from most NYSE governance requirements. Public shareholders are, structurally, along for the ride that MDP is steering.

Third, and most fundamentally, this is a technology-dependent business in a rapidly evolving market. Buffett has said repeatedly that he cannot predict which technology company will dominate in five years. The drone warfare market is evolving faster than perhaps any defense segment in history. What is state-of-the-art in GPS-denied autonomy today may be commodity capability in three years. AEVEX must run to stay in place.

Li Lu or Seth Klarman might find this interesting -- but only at a fraction of today's price. The business characteristics that attract value investors (combat-proven products, sticky government relationships, secular growth tailwinds) are genuine. But they are priced into the stock at 10x revenue and 73x EBITDA. Value investing requires buying good businesses at below-intrinsic-value prices. At $39, AVEX is a good business at 2-3x intrinsic value.

Risk Inversion: What Could Destroy This Business?

Inverting, the catastrophic scenarios:

  1. The EUCOM Cliff: Q1 2026's 283% revenue growth is almost entirely one contract. Defense contracts have defined scopes and timelines. When the EUCOM Deep Strike deliveries are complete, what fills the void? The $8.1B pipeline is impressive on paper, but at a 28.4% win rate, only ~$2.3B converts -- and over what timeframe? A single-quarter revenue miss after this growth rate would trigger a Wile E. Coyote moment in the stock.

  2. The Anduril Threat: Palmer Luckey's Anduril is building an autonomous weapons platform with Silicon Valley engineering talent, $28B+ in private capital, and a CEO who understands software as well as any founder in tech. If Anduril wins the next major UAS competition that AEVEX is pursuing, the narrative shifts from "combat-proven winner" to "legacy drone maker being disrupted by software-native competitor." Narrative shifts in small-cap defense stocks are brutal.

  3. The PE Exit Cascade: MDP's 79.1% stake will be sold. The only question is when and at what price. Lockup expiration, secondary offerings, and block trades will create persistent selling pressure for years. This is not a concern of possibility but of certainty. The float is approximately 20% of shares outstanding. Any meaningful MDP selling dwarfs daily trading volume.

  4. Margin Reality Check: Gross margins declined from 28.1% to 21.8% in one year as production scaled. If high-volume drone manufacturing is inherently a low-margin business (which is what the evidence suggests -- these are expendable munitions, not high-value platforms), then the path to profitability is much longer than the market assumes. At 15% terminal EBITDA margins (defense industry average), the DCF yields $10-18 per share.

Valuation Philosophy: The Price of Excitement

The market is paying a 117% premium above our accumulate price ($18) and a 225% premium above our strong buy price ($12). What you are paying for at $39 is not the business as it exists today -- you are paying for the dream of what it could become: a scaled, profitable, multi-billion-dollar autonomous weapons platform company.

That dream may well come true. The tailwinds are real. Defense budgets are expanding globally. Drone warfare is replacing manned platforms. AEVEX has genuine capabilities and a track record of delivery.

But the question is not whether the dream is plausible. The question is whether the dream is priced correctly. And at 10x trailing revenue for a company that has never generated positive annual free cash flow, the answer is unambiguously no.

The Patient Investor's Path

The right approach to AEVEX is watchful patience:

  1. Add to the watchlist immediately. This is a business worth following closely. The drone warfare megatrend is real, and AEVEX is one of the few pure-play public investments in the space.

  2. Wait for the lockup expiration (~October 2026). MDP will sell. The stock will fall. How far it falls will tell you how much of the current price is euphoria versus substance.

  3. Demand 2-3 quarters of public earnings. Let management demonstrate they can forecast, deliver, and communicate with public market investors. The transition from PE-backed private company to public company is harder than it looks.

  4. Set alerts at $18 and $12. These are the prices where the risk-reward becomes favorable. At $18, you are paying ~2.5x forward revenue for a growing defense tech company -- reasonable but not bargain. At $12, you are getting a genuine value investment in a company with structural tailwinds.

  5. If the stock never comes down, accept that you missed it. Missing a good investment at a bad price is not a mistake. Buying a good investment at a terrible price is.

The hardest discipline in investing is watching a stock you like go up without you. AEVEX may double again from here on defense sector momentum. It does not matter. What matters is whether the price you pay provides an adequate margin of safety against the substantial risks this business faces. At $39, it does not. At $12-18, it might. That is the only calculation that matters.

Executive Summary

AEVEX Corp is a Solana Beach, California-based defense technology company that went public three days ago, raising $320M at $20/share on the NYSE. The stock has nearly doubled to $39, giving it a market cap of approximately $4.36B. AEVEX designs and manufactures autonomous unmanned aerial systems (UAS), unmanned surface vehicles, and provides full-spectrum airborne ISR services. Its flagship product is the Phoenix Ghost family of loitering munitions, made famous through deliveries to Ukraine. The company operates two segments: Tactical Systems (autonomous drones) and Global Solutions (ISR operations, aircraft modification). Revenue was $432.9M in 2025 with a net loss of $16.8M, and Q1 2026 preliminary results show explosive 283% YoY growth to $200-208M, driven by the $645.7M EUCOM Deep Strike contract.

Thesis in 3 sentences: AEVEX is a legitimate defense technology company with combat-proven products, proprietary autonomy software (CompassX), and massive tailwinds from global rearmament and the drone warfare revolution. However, at $39 per share (nearly 2x IPO price), the stock is priced for perfection at ~10x 2025 revenue and ~73x 2025 Adjusted EBITDA, with extreme revenue concentration in a single EUCOM contract, negative free cash flow, controlled governance by Madison Dearborn Partners, and a $367.5M Tax Receivable Agreement that structurally drains cash from public shareholders. This is a WAIT -- the business is real but the valuation requires flawless execution with zero margin of safety.

Phase 0: Opportunity Identification (Klarman)

Why Does This Stock Demand Attention?

  1. Drone Warfare Megatrend: Ukraine produced ~4M drones in 2025 alone. The U.S. Army plans to acquire "several million drones" within 2-3 years. NATO is targeting 5% GDP defense spending by 2035 (vs. prior 2%). This is a secular shift in warfare, not a cyclical uptick.

  2. Combat-Proven Products: Over 5,000 Phoenix Ghost systems delivered under $582M in Pentagon contracts. This is not a concept company -- it has shipped product to active combat zones.

  3. IPO Pop Creates Future Entry Opportunity: The stock nearly doubled in 3 days. IPO euphoria and defense sector momentum are driving price. History suggests most defense tech IPOs give back 30-50% of their initial pop within 6-12 months as lockup expiration looms and reality sets in.

  4. Proprietary Technology: CompassX GPS-denied navigation and autonomy engine is differentiated. Nine issued patents (expiring 2038-2043) plus 8 pending. This is not a commodity assembler.

Why Is Patience Required?

  1. Valuation is extreme: $4.36B market cap on $432.9M 2025 revenue = 10x sales. Even using annualized Q1 2026 ($800M), that is still 5.5x revenue for a money-losing defense contractor.

  2. Insider lockup: Madison Dearborn Partners holds 79.1% voting control. The 180-day lockup expiration (approximately October 2026) will create significant selling pressure.

  3. No operating history as a public company: Zero quarterly earnings reports filed. No track record of managing Wall Street expectations.

  4. Negative FCF: Free cash flow was -$105.1M in 2025. The company is burning cash while scaling.

Phase 1: Risk Analysis (Inversion)

How Could This Investment Lose 50%+ Permanently?

  1. EUCOM Contract Cliff: Q1 2026 revenue growth of 283% is almost entirely from a single $645.7M EUCOM Deep Strike contract. If this contract is not renewed, extended, or replaced with comparable programs, revenue could collapse back toward the ~$400M baseline. At 10x sales, a revenue miss would be devastating.

  2. Competition from Well-Funded Rivals: Anduril Industries ($28B+ private valuation), Shield AI, AeroVironment (AVAV, $14B market cap), and Kratos (KTOS) are all pursuing the same autonomous systems market. AEVEX is small relative to these competitors. A technology breakthrough by a competitor could erode the CompassX advantage.

  3. Margin Deterioration: Gross margins fell from 28.1% (2024) to 21.8% (2025) as the company scaled manufacturing for major programs. If volume contracts compress margins further, the path to profitability extends beyond current expectations.

  4. Madison Dearborn Exit Overhang: MDP holds 79.1% and will eventually sell. This represents a massive supply of shares. The lockup expiration (~October 2026) and subsequent secondary offerings will weigh on the stock for years.

  5. Tax Receivable Agreement (TRA): An estimated $367.5M in payments over ~15 years at 85% of certain tax savings. This is a structural cash drain that benefits pre-IPO holders at the expense of public shareholders. It is one of the most investor-unfriendly features seen in recent defense IPOs.

  6. Government Budget Risk: 78% of 2025 revenue came from the U.S. Government. A change in administration priorities, continuing resolution, or sequestration could freeze contract awards. Defense budgets are politically vulnerable despite current bipartisan support.

  7. CEO Transition: Roger Wells became CEO in November 2025 -- just 5 months before the IPO. Short tenure creates execution uncertainty despite his strong resume.

Bear Case (3 Sentences)

AEVEX is a single-program story dressed up as a defense tech platform; strip out the EUCOM Deep Strike contract and revenue growth evaporates. At $39/share and 10x 2025 revenue, the market is pricing in flawless execution of an $8.1B pipeline by a newly public company with negative free cash flow, deteriorating margins, and a controlling shareholder preparing to exit. If EUCOM deliveries slow, margins fail to recover, or the lockup expiration triggers a sell-off, 50%+ downside is entirely plausible.

Risk Register

Risk Probability Impact Expected Loss
EUCOM contract concentration/cliff 30% -45% -13.5%
Lockup expiration selling pressure 70% -20% -14.0%
Competitive displacement (Anduril et al.) 20% -35% -7.0%
Continued margin deterioration 40% -25% -10.0%
Government budget/sequestration 15% -30% -4.5%
CEO transition execution risk 15% -20% -3.0%
Weighted expected loss -52.0%

Phase 2: Financial Analysis

Income Statement

Metric 2024 2025 Q1 2026 (prelim)
Revenue ~$392M $432.9M $200-208M
Revenue Growth -- +10.4% +283% YoY
Gross Margin 28.1% 21.8% Not disclosed
Net Income -$78.6M -$16.8M $19-22.5M
Adj. EBITDA -- $37.6M ~$35M
Adj. EBITDA Margin -- 8.7% ~17%
R&D (LTM Dec 2025) -- $68.8M --
R&D % of Revenue -- 15.9% --

Key observations:

  • The net loss improvement from -$78.6M to -$16.8M shows operational progress, but profitability is not yet established on an annual basis
  • Q1 2026 is transformational: $19-22.5M net income in one quarter vs. full-year 2025 net loss of $16.8M
  • R&D at 15.9% of revenue is high for a defense contractor, reflecting the growth-stage investment profile
  • Annualized Q1 2026 revenue of ~$800M+ implies near-doubling from 2025, but this depends on sustained EUCOM deliveries

Balance Sheet (Pre-IPO)

Metric Value
Pre-IPO Debt ~$257.8M (to be repaid with IPO proceeds)
IPO Gross Proceeds $320M
Net IPO Proceeds (est.) ~$280M after fees
Post-IPO Cash (est.) ~$60-80M (after debt repayment)
TRA Obligation ~$367.5M over 15 years
Shares Outstanding 111.83M

Key observations:

  • The $320M IPO essentially refinanced the balance sheet -- proceeds went to repay $257.8M in debt, leaving limited growth capital
  • The TRA obligation ($367.5M) is effectively a second class of debt that benefits MDP at public shareholders' expense
  • Post-IPO balance sheet is clean from a traditional debt perspective, but the TRA creates a long-duration cash drain

Cash Flow

Metric 2025
Adj. EBITDA $37.6M
Free Cash Flow -$105.1M
FCF Margin -24.3%
Cumulative IRAD+CRAD (2024-2025) $104.2M

Key observations:

  • Negative FCF of -$105.1M in 2025 is deeply concerning. The company is consuming cash while growing.
  • The gap between Adj. EBITDA ($37.6M) and FCF (-$105.1M) implies ~$143M in working capital consumption, capex, and other cash uses
  • R&D investment of $104.2M over two years is necessary for competitive positioning but extends the timeline to sustainable cash generation
  • Management targets >30% IRR on internal R&D with ~2-year payback -- if achieved, this spending is value-accretive

Backlog & Pipeline

Metric Value
Funded Backlog $503M (~14 months at 2025 run rate)
Total Pipeline $8.1B
Phoenix Ghost Deliveries 4,400+ units (sole-sourced)
EUCOM Deep Strike Contract $645.7M
Combined Flagship Programs $1.2B+
Competitive Win Rate 28.4% on full-and-open
Recompete/Option Win Rate 99% value-weighted

Phase 3: Moat Assessment

Moat Sources

1. Security Clearances & Classified Relationships (Narrow but Sticky) AEVEX operates in classified environments requiring Top Secret/SCI clearances. Approximately 30% of the workforce are military veterans with SOF, USAF, and intelligence community backgrounds. This creates a workforce moat -- you cannot easily hire these people, and competitors cannot easily enter classified programs. Once awarded a contract at the classified level, switching costs are astronomically high.

2. CompassX Proprietary Autonomy Platform (Narrow, Potentially Widening) The CompassX GPS-denied navigation system is the company's most differentiated technology asset. In modern warfare where GPS jamming is standard, the ability to navigate autonomously using visual odometry and multi-sensor fusion is mission-critical. Nine issued patents (2038-2043 expiry) provide some protection, but the real moat is the accumulation of real-world combat data that trains and improves the algorithms.

3. Combat-Proven Track Record (Narrow but Meaningful) Over 5,000 Phoenix Ghost systems delivered to active combat theaters. "Nine-day order-to-delivery" capability. This cannot be replicated by a startup with a PowerPoint deck. The DoD strongly prefers vendors who have already demonstrated reliability in combat conditions. The 99% recompete win rate confirms this advantage.

4. ForgeX Battlefield Manufacturing (Unique Capability) AEVEX claims to be the only U.S. defense company with deployable, forward-positioned drone manufacturing capability. If validated at scale, this is a significant differentiator for expeditionary warfare scenarios.

5. Vertical Integration Complete control from software development through manufacturing, testing (120-acre FAA-approved Florida test range), and deployment. Production capacity of 1,000+ unmanned systems per month across 100,000 sq ft of manufacturing footprint in Florida, California, Virginia, and Ohio.

Moat Width: NARROW

The moat is real but narrow. The defense autonomous systems market is attracting massive capital inflows. Anduril ($28B+ valuation), Shield AI, AeroVironment, Kratos, L3Harris, and Northrop Grumman are all investing heavily. AEVEX's advantages are genuine but not insurmountable -- CompassX is differentiated today but could be matched by well-funded competitors within 3-5 years. The classified relationship moat and combat track record are harder to replicate and represent the most durable competitive advantages.

Moat Trend: WIDENING (conditionally)

If AEVEX can sustain its 99% recompete win rate and expand into international FMS markets (55 allied-nation engagements in development), the moat widens. But this depends on continued R&D investment and successful program execution. The moat is widening only if management executes -- it does not widen on autopilot.

Phase 4: Synthesis & Valuation

Comparable Company Valuation

Company Ticker Revenue EV/Revenue EV/EBITDA Notes
AeroVironment AVAV ~$750M ~6.0x ~35x Closest peer; small UAS + loitering munitions
Kratos KTOS ~$1.1B ~4.5x ~40x Drone targets + tactical UAS
L3Harris LHX ~$21B ~2.2x ~15x Large-cap ISR + EW
AEVEX AVEX $433M (2025) ~10x ~73x Premium to all peers
AEVEX (2026E) AVEX ~$800M ~5.5x ~25-30x If Q1 pace sustained

Key observations:

  • At $39/share, AEVEX trades at a significant premium to every comparable company on 2025 financials
  • Using annualized 2026 revenue (~$800M), the multiple compresses to ~5.5x -- still above Kratos and L3Harris, roughly in line with AVAV
  • The premium is justified ONLY if Q1 2026 growth rates are sustained throughout the year AND margins expand
  • EV/EBITDA of ~73x on 2025 numbers is indefensible; only the 2026 forward numbers make the valuation remotely reasonable

DCF Estimate (Simplified)

Assumptions:

  • 2026E Revenue: $800M (annualized Q1)
  • 2027E Revenue: $1.0B (25% growth as pipeline converts)
  • Terminal EBITDA margin: 15% (defense services average)
  • Terminal growth: 3%
  • Discount rate: 12% (high for IPO uncertainty)
  • 2027E EBITDA: $150M
  • Terminal Value: $150M x (1.03) / (0.12 - 0.03) = $1.72B
  • Discounted back 2 years: $1.37B
  • Plus interim FCF (assume breakeven 2026-2027): ~$0
  • Enterprise Value: ~$1.4B
  • Less TRA PV (~$250M): ~$1.15B
  • Equity Value: ~$1.15B
  • Per share: ~$10.30

Bull Case DCF (aggressive):

  • 2028E Revenue: $1.5B (pipeline acceleration)
  • Terminal EBITDA margin: 18%
  • Terminal EBITDA: $270M
  • Terminal Value: $3.1B, discounted: $2.2B
  • Less TRA: $2.0B
  • Per share: ~$17.80

Key finding: Even under aggressive growth assumptions, the DCF suggests fair value of $10-18 per share. The current price of $39 is pricing in either (a) much higher terminal margins than defense contractors typically achieve, (b) revenue well above $2B, or (c) IPO euphoria that will correct.

Entry Prices

Level Price Implied EV/2026E Rev Rationale
Strong Buy $12.00 ~1.7x Deep value; post-lockup washout + market correction
Accumulate $18.00 ~2.5x Reasonable defense tech multiple; near IPO price
Fair Value $25.00 ~3.5x Moderate growth premium; still requires execution
Current $39.01 ~5.5x Euphoria premium; priced for perfection

Investment Decision

WAIT -- Do Not Buy at Current Prices

Rationale:

  1. Valuation is 2-3x fair value: The DCF analysis suggests $10-18 per share fair value range. At $39, you are paying for a future that assumes perfect execution, sustained 50%+ revenue growth, significant margin expansion, and no competitive displacement.

  2. Lockup expiration creates a catalyst for entry: In approximately October 2026, MDP's 79.1% stake becomes eligible for sale. This typically triggers 20-40% declines in newly public stocks, particularly those that have rallied significantly from IPO price.

  3. The business is real but unproven as a public company: AEVEX has legitimate technology, combat-proven products, and massive tailwinds. But it has never reported a quarterly earnings release, never navigated Wall Street expectations, and never demonstrated FCF generation. Let the company prove itself for 2-3 quarters before paying a premium.

  4. The TRA and governance structure penalize public shareholders: 79.1% voting control by MDP + $367.5M TRA + controlled company status = public shareholders are structurally disadvantaged. You need a larger margin of safety to compensate for this governance discount.

  5. Better entry points will come: Defense IPOs typically give back their initial pops. Joby Aviation (JOBY), Rocket Lab (RKLB), and others followed this pattern. Patient investors who waited 6-12 months post-IPO were rewarded with 30-50% lower entry prices.

When to Revisit

  • After Q2 2026 earnings (first full quarter as public company)
  • After lockup expiration (~October 2026)
  • If shares trade back to $18-20 range (near IPO price)
  • After MDP completes initial secondary offering(s)

Appendix: Key Data Sources

  • AEVEX Corp S-1 Filing (SEC EDGAR)
  • AEVEX Corp Press Release: IPO Pricing (April 16, 2026)
  • StockAnalysis.com: AVEX price data
  • Washington Technology: IPO coverage
  • The Defense Post: Valuation analysis
  • Bloomberg: Post-IPO trading coverage
  • Wikipedia / Breaking Defense: Phoenix Ghost program details